CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. CSL Behring’s products are also used in cardiac surgery, organ transplantation, burn treatment and more

Products

Events

Events not available

News

ICU Management

Key decisions in a goal-directed coagulation management approach

2018 16 Oct

An individualised goal-directed approach to managing coagulopathy is recommended to treat bleeding trauma patients. Severe trauma is a great burden to society, with millions of victims worldwide. If trauma patients are hazardly bleeding, surgical bleeding requires the surgeon to fix the problem, while coagulopathy requires management... Read more

ICU Management

Evidence for using first-line coagulation factor concentrates for trauma- induced coagulopathy

2018 16 Oct

Fibrinogen limits coagulopathy and massive bleeding, has less transfusion requirements and thereby decreases the risk of multi-organ failure in trauma patients. What stops the bleeding? Haemostatic therapy aims to stop the bleeding, but is it a concentration of coagulation factors, mainly assessed by international normalised ratio (INR)... Read more

ICU Management

Implementation of a revised trauma management protocol

2018 16 Oct

Goal-directed therapy of coagulopathy is recommended for trauma patients. Can guidelines direct our strategy? When presented with bleeding trauma patients, our management strategy may be directed by guidelines, e.g. the European trauma guideline (Rossaint et al. 2016). This recommends treatment with fibrinogen concentrate or cryoprecipitate... Read more

ICU Management

Treatment of bleeding patients during therapy with direct oral anticoagulants

2017 15 Sep

Results from the French registry: GIHP-NACO  Presents results from a registry detailing information about the management of bleeding patients in the emergency room, operating room or intensive care unit during therapy with direct oral anticoagulants.   Background   There is a large literature on the efficacy of direct oral anticoagulants... Read more

ICU Management

Fibrinogen concentrate in elective complex cardiac surgery: a monocentric trial

2017 15 Sep

Presents the results from a randomised controlled trial which aimed to determine if fibrinogen concentrate infusion reduces intraoperative blood loss in cardiac surgery patients.   Background   Excessive bleeding is a common complication in cardiac surgery, and may result in the need for red blood cell (RBC) transfusion. Intraoperative... Read more

ICU Management

Treatment of trauma-induced coagulopathy with factor concentrates

2017 15 Sep

RETIC study  Presents results of the RETIC study that compared treatment of trauma-induced coagulopathy using coagulation factor concentrates or fresh frozen plasma.   Background   Trauma-induced coagulopathy (TIC) represents a clinical picture resulting from severity of injury, hypoperfusion, blood loss, consumption, dilution and... Read more

Jobs not available

Catalogue

    Catalogue not available

Emil-von-Behring Straße,
Marburg
35041
Germany
+49 (0) 6421 39-12

White Papers - Case Studies

Not available

Videos

    Videos not available

Articles

ICU Management

Key decisions in a goal-directed coagulation management approach

2018 16 Oct

An individualised goal-directed approach to managing coagulopathy is recommended to treat bleeding trauma patients. Severe trauma is a great burden to society, with millions of victims worldwide. If trauma patients are hazardly bleeding, surgical bleeding requires the surgeon to fix the problem, while coagulopathy requires management... Read more

ICU Management

Evidence for using first-line coagulation factor concentrates for trauma- induced coagulopathy

2018 16 Oct

Fibrinogen limits coagulopathy and massive bleeding, has less transfusion requirements and thereby decreases the risk of multi-organ failure in trauma patients. What stops the bleeding? Haemostatic therapy aims to stop the bleeding, but is it a concentration of coagulation factors, mainly assessed by international normalised ratio (INR)... Read more

ICU Management

Implementation of a revised trauma management protocol

2018 16 Oct

Goal-directed therapy of coagulopathy is recommended for trauma patients. Can guidelines direct our strategy? When presented with bleeding trauma patients, our management strategy may be directed by guidelines, e.g. the European trauma guideline (Rossaint et al. 2016). This recommends treatment with fibrinogen concentrate or cryoprecipitate... Read more

ICU Management

Treatment of bleeding patients during therapy with direct oral anticoagulants

2017 15 Sep

Results from the French registry: GIHP-NACO  Presents results from a registry detailing information about the management of bleeding patients in the emergency room, operating room or intensive care unit during therapy with direct oral anticoagulants.   Background   There is a large literature on the efficacy of direct oral anticoagulants... Read more

ICU Management

Fibrinogen concentrate in elective complex cardiac surgery: a monocentric trial

2017 15 Sep

Presents the results from a randomised controlled trial which aimed to determine if fibrinogen concentrate infusion reduces intraoperative blood loss in cardiac surgery patients.   Background   Excessive bleeding is a common complication in cardiac surgery, and may result in the need for red blood cell (RBC) transfusion. Intraoperative... Read more

ICU Management

Treatment of trauma-induced coagulopathy with factor concentrates

2017 15 Sep

RETIC study  Presents results of the RETIC study that compared treatment of trauma-induced coagulopathy using coagulation factor concentrates or fresh frozen plasma.   Background   Trauma-induced coagulopathy (TIC) represents a clinical picture resulting from severity of injury, hypoperfusion, blood loss, consumption, dilution and... Read more